KNOS vs. FBT, SOPH, PRSM, KAPE, TRST, GBG, ATG, LTG, ALFA, and IMO
Should you be buying Kainos Group stock or one of its competitors? The main competitors of Kainos Group include First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (FBT), Sophos Group plc (SOPH.L) (SOPH), Blue Prism Group (PRSM), Kape Technologies (KAPE), Trustpilot Group (TRST), GB Group (GBG), Auction Technology Group (ATG), Learning Technologies Group (LTG), Alfa Financial Software (ALFA), and IMImobile (IMO). These companies are all part of the "software - application" industry.
Kainos Group (LON:KNOS) and First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT) are both computer and technology companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings, community ranking and profitability.
In the previous week, Kainos Group and Kainos Group both had 1 articles in the media. First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's average media sentiment score of 1.53 beat Kainos Group's score of 0.00 indicating that First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation is being referred to more favorably in the news media.
Kainos Group currently has a consensus price target of GBX 1,198.75, indicating a potential upside of 4.06%. Given Kainos Group's higher probable upside, equities research analysts plainly believe Kainos Group is more favorable than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation.
Kainos Group has higher revenue and earnings than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation is trading at a lower price-to-earnings ratio than Kainos Group, indicating that it is currently the more affordable of the two stocks.
Kainos Group received 170 more outperform votes than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation when rated by MarketBeat users. Likewise, 72.02% of users gave Kainos Group an outperform vote while only 66.67% of users gave First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation an outperform vote.
46.3% of Kainos Group shares are held by institutional investors. 37.5% of Kainos Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Kainos Group has a net margin of 12.74% compared to First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's net margin of 0.00%. Kainos Group's return on equity of 34.05% beat First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's return on equity.
Summary
Kainos Group beats First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation on 12 of the 14 factors compared between the two stocks.
Get Kainos Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for KNOS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kainos Group Competitors List
Related Companies and Tools
